Enanta Pharmaceuticals Accounts Payables 2011-2026 | ENTA

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Enanta Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.95 M	8 M	4.1 M	6 M	9.54 M	5.74 M	6.69 M	4.74 M	3.71 M	3.38 M	1.54 M	1.87 M	1.48 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.54 M	1.48 M	4.52 M

Quarterly Accounts Payables Enanta Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.55 M	4.76 M	4.73 M	8 M	10.7 M	6.73 M	9.33 M	4.1 M	7.93 M	11.8 M	4.35 M	6 M	1.24 M	5.98 M	7.84 M	9.54 M	5.9 M	9.54 M	6.3 M	5.74 M	5.74 M	5.74 M	6.6 M	6.69 M	6.69 M	6.69 M	5.62 M	4.74 M	4.74 M	4.74 M	3.27 M	3.71 M	3.71 M	3.71 M	1.95 M	3.38 M	3.38 M	3.38 M	2.77 M	1.54 M	1.54 M	1.54 M	567 K	1.87 M	1.87 M	1.87 M	840 K	1.48 M	1.48 M	1.48 M	-	1.85 M	1.85 M	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
11.8 M	567 K	4.64 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
AgeX Therapeutics AGE	1.41 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Adagene ADAG	4.24 M	$ 1.65	7.91 %	$ 92.9 M	China
Arrowhead Pharmaceuticals ARWR	17.7 M	$ 66.05	2.3 %	$ 8.83 B	USA
Autolus Therapeutics plc AUTL	1.97 M	$ 1.52	-16.3 %	$ 388 M	Britain
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Biogen BIIB	424 M	$ 184.48	-1.67 %	$ 26.9 B	USA
AVROBIO AVRO	27 K	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 4.25	1.67 %	$ 9.25 B	Israel
BeiGene, Ltd. BGNE	405 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	486 K	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	10.1 M	-	-7.31 %	$ 87 M	USA
Bristol-Myers Squibb Company BMY	3.6 B	$ 55.71	-0.28 %	$ 113 B	USA
Codiak BioSciences CDAK	1.84 M	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	3.46 M	-	1052.0 %	$ 415 M	USA
Cerevel Therapeutics Holdings CERE	11.9 M	-	-	$ 7.29 B	USA
Acasti Pharma ACST	601 K	-	4.01 %	$ 150 M	Canada
Zai Lab Limited ZLAB	101 M	$ 18.37	-0.97 %	$ 18.2 B	China
Coherus BioSciences CHRS	35.2 M	$ 1.61	-5.03 %	$ 152 M	USA
Catalyst Biosciences CBIO	355 K	$ 10.84	0.46 %	$ 714 M	USA
Caladrius Biosciences CLBS	1.28 M	-	-16.75 %	$ 25.8 M	USA
Celldex Therapeutics CLDX	3.26 M	$ 25.59	-6.54 %	$ 1.65 M	USA
Clearside Biomedical CLSD	2.2 M	-	-	$ 25.3 M	USA
Chimerix CMRX	2.85 M	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	8.13 M	-	-15.15 %	$ 60.3 M	Britain
Corcept Therapeutics Incorporated CORT	15.4 M	$ 37.35	-0.4 %	$ 3.86 B	USA
Catalyst Pharmaceuticals CPRX	16.6 M	$ 23.18	2.02 %	$ 2.75 B	USA
Albireo Pharma ALBO	6.52 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	3.81 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA
AlloVir ALVR	247 K	-	4.14 %	$ 49.1 M	USA
Crinetics Pharmaceuticals CRNX	5.85 M	$ 55.11	3.49 %	$ 4.45 B	USA
CRISPR Therapeutics AG CRSP	14.7 M	$ 55.17	2.47 %	$ 4.65 B	Schweiz
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Zentalis Pharmaceuticals ZNTL	14.9 M	$ 3.53	-5.75 %	$ 231 M	USA
Ampio Pharmaceuticals AMPE	750 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	30.5 M	$ 29.43	6.09 %	$ 1.43 B	USA